NP-G2-044

DRUG2 trials

Sponsors

Novita Pharmaceuticals, Inc.

Conditions

Advanced or Metastatic Treatment-refractory Solid Tumor MalignanciesBreast CancerColon CancerEsophagus CancerLiver CancerLung CancerOvary CancerPancreas Cancer

Phase 1

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

CompletedNCT03199586

Novita Pharmaceuticals, Inc.Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies, Breast Cancer, Colon Cancer +6

Start: 2017-12-21End: 2020-05-07Updated: 2025-07-20

Phase 2

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Active, not recruitingNCT07109414

Novita Pharmaceuticals, Inc.Platinum-resistant Ovarian Cancer

Start: 2025-12-29End: 2029-10-24Target: 380Updated: 2026-03-09

Related Papers

Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.

Journal of Clinical Oncology2021-05-2017 citations